anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ventricular tachycardia (VT) is a malignant cardiac arrhythmia leading to a sudden abolition of cardiac function directly followed by a shortage of oxygen supply to essential organs such as the brain and heart. For this reason, VT is a cardiac emergency and should be treated within seconds to minutes before irreversible and potentially fatal organ damage follows. Current treatment options are limited to anti-arrhythmic drugs, an implantable cardioverter defibrillator (ICD), and invasive catheter ablation. Unfortunately, invasive cardiac VT ablation has the lowest success rate and the highest complication rates among all arrhythmia ablations.

Since the first case series published by Cuculich et al. (2017) and the first prospective trial published by Robinson et al. (2019), stereotactic arrhythmia radiotherapy (STAR) has evolved as a new treatment modality for patients with ventricular tachycardia refractory to conventional therapies. Patients are treated with a single radiotherapy fraction of 25 Gy at the determined pro-arrhythmic cardiac region with the use of standard stereotactic radiotherapy techniques. Experience with STAR is steadily growing worldwide. In the systematic review by Van der Ree et al. (2020), a reduction of \>85% in VT episodes with a simultaneously promising safety profile was shown.

The mechanism of action of STAR is not yet fully known and is yet to be elucidated. The pathophysiological mechanism of VT relies on re-entry due to zigzag conduction by the surviving myocardial fibers in previously damaged heart tissue. At first, it was hypothesized that inducing cell-death by ionizing radiation leads to dense transmural fibrosis. As mature myocardial fibrosis is not able to propagate electrical activation this may lead to the abolishment of the zigzag conduction herewith reducing the chance of re-entry and VT. Fibrosis maturation takes several weeks to months to complete. However, the anti-arrhythmic effects seem to occur earlier. In preclinical studies, early electrophysiological alterations were demonstrated (Zhang et al. 2021). The gap-junction protein connexion-43 (Cx43) and the voltage gated sodium channels were upregulated, leading to a supraphysiological state with increased conduction velocity. Since a slow conduction pathway is required for re-entry, this could explain the timing of the observed effect, although the exact mechanism of action remains to be elucidated.

In the STARNL-2 study we aim to confirm our STARNL-1 pilot (6 patients) efficacy and safety data in a larger cohort and obtain insights in the electro-anatomical alterations of stereotactic arrhythmia radiotherapy in patients with therapy refractory ventricular tachycardia.
In some patients Levetiracetam causes behavioral abnormalities. The incidences of behavioral abnormalities in the myoclonic and primary generalized tonic-clonic seizure studies were comparable to those of the adult and pediatric partial onset seizure studies.

A total of 13.3% of adult Levetiracetam-treated patients and 37.6% of pediatric Levetiracetam-Treated patients (4 to 16 years of age) compared to 6.2% and 18.6% of adult and pediatric placebo patients respectively, experienced non-psychotic behavioral symptoms (reported as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, hyperkinesias, irritability, nervousness, neurosis, and personality disorder). A randomized double-blind, placebo-controlled study was performed to assess the neurocognitive and behavioral effects of Levetiracetam as adjunctive therapy in pediatric patients (4 to 16 years of age). The results from an exploratory analysis indicated a worsening in Levetiracetam-Treated patients on aggressive behavior (one of eight behavior dimensions) as measured in a standardized and systematic way using a validated instrument, the Achenbach Child Behavior Checklist (CBCL/6-18).

In pediatric patients 1 month to < 4 years of age, irritability was reported in 11.7% of the Levetiracetam-Treated patients compared to 0% of placebo patients.

A total of 1.7% of adult Levetiracetam-treated patients discontinued treatment due to behavioral adverse events, compared to 0.2% of placebo patients. The treatment dose was reduced in 0.8% of adult Levetiracetam-Treated patients and in 0.5% of placebo patients. Overall, 10.9% of Levetiracetam-Treated pediatric patients experienced behavioral symptoms associated with discontinuation or dose reduction, compared to 6.2% of placebo patients. 

One percent of adult Levetiracetam-Treated patients, 2% of children 4 to 16 years of age, and 17% of children 1 month to <4 years of age experienced psychotic symptoms, compared to 0.2%, 2%, and 5% respectively, in the placebo patients. In the controlled study that assessed the neurocognitive and behavioral effects of Levetiracetam in pediatric patients 4 to 16 years of age, 1 (1.6%) Levetiracetam-Treated patient experienced paranoia compared to no placebo patients. There were 2 (3.1%) Levetiracetam-Treated patients that experienced confusional state compared to no placebo patients [see Use in Specific Populations (8.4)].

Two (0.3%) adult Levetiracetam-Treated patients were hospitalized and their treatment was discontinued due to psychosis. Both events, reported as psychosis, developed within the first week of treatment and resolved within 1 to 2 weeks following treatment discontinuation. There was no difference between drug and placebo-treated patients in the incidence of the pediatric patients who discontinued treatment due to psychotic and non-psychotic adverse reactions. 

The above psychiatric signs and symptoms should be monitored.
PURPOSE: An inhibitor and a breaker of an advanced glycation end-products (AGEs)-induced crosslink, containing chebulic acid as an active ingredient are provided to suppress and break a crosslink between AGEs containing chebulic acid and proteins, thereby preventing or treating diseases. CONSTITUTION: A glycation inhibitor contains chebulic acid as an active ingredient and suppresses AGE formation caused by collagen. A crosslink inhibitor contains chebulic acid as an active ingredient and suppresses a crosslink between AGEs and proteins. A crosslink breaker contains chebulic acid as an active ingredient and breaks a crosslink between AGEs and proteins. A functional cosmetic composition contains chebulic acid, a Terminalia chebula Retz. extract containing chebulic acid, or a Terminalia chebula Retz. fraction containing chebulic acid as an active ingredient. The functional cosmetic composition improves anti-wrinkling or antiaging effects or skin elasticity.
Exercise intolerance and fatigue are the most common symptoms in patients with chronic COVID after hospital discharge. Muscle deconditioning, dysautonomia, and exercise hyperventilation have been proposed as potential mechanisms contributing to exercise functional capacity limitation in Long-COVID. Along this line, combined exercise training or inspiratory muscle training (IMT) alone have already been demonstrated to be feasible therapeutic options for Long-COVID patients. However, we do not have evidence about the effects of a home-based IMT program for 12-week on peak oxygen consumption (peakVO2). in patients chronic COVID (\>3 months) after hospital discharge.

This is a prospective study, blinded for the evaluator, randomized (1:1) to receive standard management alone or combined with a program of IMT that will be carried out in a single center. Patients allocated to the IMT arm will be instructed to train at home twice daily, for 20 minutes each session, using a Threshold inspiratory muscle trainer (Respironics Inc., Parsippany, NJ). They will be instructed by a physiotherapist responsible for training intervention and educated to maintain diaphragmatic breathing during the training period. The subjects will start breathing at a resistance equal to 25% to 30% of their maximal inspiratory mouth pressure (MIP) for 1 week. The respiratory therapist will examine the patients at weekly intervals by checking the diary card and measuring the MIP each time. The resistance will be modified each session according to the 25% to 30% of their MIP measured. After randomization, patients will be clinically evaluated. The primary endpoint (peakVO2) will be assessed by cardiopulmonary exercise testing (CPET) at 12-week. Patients with chronic COVID (\>3 months) after hospital discharge will be enrolled. A sample size estimation \[alfa: 0.05, power: 80%, a 15% loss rate, and at least a delta change of mean peakVO2: +3 mL/kg/min (SD±2.5)\] of 26 patients (13 per arm) would be necessary to test our hypothesis.
<P>PROBLEM TO BE SOLVED: To provide an anthraquinone derivative having reduced adverse effect and exerting a lipases activating effect which manifests an excellent decreasing effect on neutral fats, and to provide an excellent antiobesity drug, a food preparation and a cosmetic comprising the derivative.  <P>SOLUTION: The anthraquinone derivative is a compound comprising a steroid originating from vegetable and anthraquinone. The compound obtained by fermenting pulverized product of seeds, leaves or roots of Rumex japonicus, pulverized product of soy beans by Bacillus natto and then reducing the product with alkali. The antiobesity drug comprises the anthraquinone derivative exerting decreasing effect on neutral fats as a principal component. The cosmetic exerts the decreasing effect on neutral fats and comprising the anthraquinone derivative. The food preparation exerting the decreasing effect on neutral fats comprises 0.001-0.01 pts.wt. of an extract of Banaba (Lagerstroemia speciosa L Pers.) leaves and 0.01-1 pts.wt. of an extract of persimmon leaves per 1 pts.wt. of the anthraquinone derivative.  <P>COPYRIGHT: (C)2007,JPO&INPIT
OBJECTIVE: The survival outcomes of Stage IIIC1 in FIGO 2018 showed significant heterogeneity and it seems unreasonable to administer a uniform treatment regimen for Stage IIIC1 patients. This study aimed to assess the survival outcomes among patients with locally advanced cervical cancer based on various lymph node statuses, T-stage classifications, and treatment modalities.
METHODS: This is a population-based cohort study utilizing the Surveillance, Epidemiology, and End Results Program from 2004 to 2018. Propensity score-based inverse probability of treatment weighting was used to achieve covariate balance. Women with locally advanced cervical cancer on different lymph node statuses who underwent radical hysterectomy + pelvic lymphadenectomy + chemoradiotherapy, chemoradiotherapy, or radiotherapy alone were examined. Trends, patient characteristics, and survival outcomes were compared across different treatment regimens.
RESULTS: Among 8777 patients analyzed, patients with early T-stage and married were identified as independent protective factors for cancer-specific survival regardless of lymph node status. The survival outcomes ranked in descending order as follows: T1N0>T2N0>T1N1 = T2N1>T3N0>T3N1. Therefore, the FIGO Stage IIIC1 was re-stratified into IIC (T1N1+T2N1) and IIIC1(T3N1). Patients who underwent radical hysterectomy combined with adjuvant therapy exhibited superior 5-year cancer-specific survival rates compared to those treated with chemoradiotherapy among IB3, IIA2, and IIC. The therapeutic efficacy of chemoradiotherapy surpassed that of radiotherapy alone in IIIA, IIIB, IIIC1(T3N1), and IVA patients.
CONCLUSION: Restratification of Stage IIIC1 based on T-stage effectively discerns patients with divergent prognoses. Radical surgery + chemoradiotherapy is significantly associated with improved survival in early T-stage, regardless of lymph node status in locally advanced cervical cancer.
The largest multi-gene family in metazoans is the family of olfactory receptor (OR) genes. Human ORs are organized in clusters over most chromosomes and seem to include >0.1% the human genome. Because 369 out of 856 OR genes are mapped on chromosome 11 (HSA11), we sought to determine whether they mediate structural rearrangements involving this chromosome. To this aim, we analyzed 220 specimens collected during diagnostic procedures involving structural rearrangements of chromosome 11. A total of 222 chromosomal abnormalities were included, consisting of inversions, deletions, translocations, duplications, and one insertion, detected by conventional chromosome analysis and/or fluorescence in situ hybridization (FISH) and array comparative genomic hybridization (array-CGH). We verified by bioinformatics and statistical approaches the occurrence of breakpoints in cytobands with or without OR genes. We found that OR genes are not involved in chromosome 11 reciprocal translocations, suggesting that different DNA motifs and mechanisms based on homology or non-homology recombination can cause chromosome 11 structural alterations. We also considered the proximity between the chromosomal territories of chromosome 11 and its partner chromosomes involved in the translocations by using the deposited Hi-C data concerning the possible occurrence of chromosome interactions. Interestingly, most of the breakpoints are located in regions highly involved in chromosome interactions. Further studies should be carried out to confirm the potential role of chromosome territories' proximity in promoting genome structural variation, so fundamental in our understanding of the molecular basis of medical genetics and evolutionary genetics.
Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with the standard mFOLFOX chemotherapy regimen in participants with gastroesophageal or colorectal cancer.
OBJECTIVE: To explore the effect of acupuncture treatment on cerebral ischaemia-reperfusion injury (CIRI) and reveal the underlying mechanism of the effect based on nuclear receptor coactivator 4 (NCOA4) mediated ferritinophagy.
METHODS: Sprague-Dawley male rats were divided into four groups: the sham group, model group, acupuncture group, and sham acupuncture group. After 2 h of middle cerebral artery occlusion (MCAO), reperfusion was performed for 24 h to induce CIRI. The rats were treated with acupuncture at the Neiguan (PC6) and Shuigou (GV26) acupoints. Their neurological function was evaluated by taking their Bederson scores at 2 h after ischaemia and 24 h after reperfusion. Triphenyltetrazolium chloride staining was applied to assess the cerebral infarct volume at 24 h after reperfusion. The malondialdehyde (MDA) and ferrous iron (Fe2+) levels were observed after 24 h of reperfusion using an assay kit. Western blotting was performed to detect the expression of NCOA4 and ferritin heavy chain 1 (FTH1) at 24 h after reperfusion. Moreover, the colocalization of ferritin with neurons, NCOA4 with microtubule-associated protein 1 light chain 3 (LC3), and NCOA4 with ferritin was visualized using immunofluorescence staining.
RESULTS: Acupuncture significantly improved neurological function and decreased cerebral infarct volume in the acupuncture group. Following CIRI, the expression of NCOA4, LC3 and FTH1 was increased, which enhanced ferritinophagy and induced an inappropriate accumulation of Fe2+ and MDA in the ischaemic brain. However, acupuncture dramatically downregulated the expression of NCOA4, LC3 and FTH1, inhibited the overactivation of ferritinophagy, and decreased the levels of MDA and Fe2+.
CONCLUSIONS: Acupuncture can inhibit NCOA4-mediated ferritinophagy and protect neurons against CIRI in a rat model.
The invention relates to a medicine for treating the gouty nephropathy. The medicine is prepared from, by weight, 6 parts of fordiophyton fordii, 15 parts of Neottopterisantrophyoides(Christ)Ching[AspleniumantrophyoidesChrist], 9 parts of Peucedanum morisonii Bess[P.songoricum auct. Non G. Don], 15 parts of filliform cassytha herb, 9 parts of Myricaria bracteata Royle[M.alo-pecuroides Schreuk], 12 parts of Pygmaeopremna herbacea(Roxb.)Moldenke[Premna herbacea Roxb.], 6 parts of rhizoma dioscoreae hypoglaucae, 10 parts of rust-coloured crotalaria herb with roots, 15 parts of passion flowers, 9 parts of rubus buergeri leaves and 6 parts of eragrostis ferruginea. The medicine has the advantages that fordiophyton fordii clears away heat for diuresis; Neottopterisantrophyoides(Christ)Ching[AspleniumantrophyoidesChrist] induces diuresis for treating stranguria and removes toxin for detumescence; Peucedanum morisonii Bess[P.songoricum auct. Non G. Don] expels wind and removes cold, and regulates qi to alleviate pain; filliform cassytha herb clears heat and promotes diuresis; Myricaria bracteata Royle[M.alo-pecuroides Schreuk] raises yang for divergency, and removes toxin and dispels wind; Pygmaeopremna herbacea(Roxb.)Moldenke[Premna herbacea Roxb.] promotes blood circulation to arrest pain, and dispels wind and eliminates dampness; rhizoma dioscoreae hypoglaucae removes dampness and turbidity, and dispels wind and stops diarrhea; rust-coloured crotalaria herb with roots nourishes spleen and kidney, induces urination, and removes swelling and toxin; passion flowers dispel wind, eliminate dampness and invigorate blood circulation; rubus buergeri leaves nourish yin and boost essence; eragrostis ferruginea invigorates blood circulation and disperses blood stasis; the medicine components are used in cooperation and play a role in combining dredging and tonifying, considering qi and pathogen at the same time, conducting nourishing without stasis, eliminating evil without hurting bodies, tonifying kidney for removing tubidity, and removing dampness and dispersing blood stasis; it is proved through clinical experiments that the medicine can safely and effectively treat the gouty nephropathy.
BACKGROUND: Glaucoma staging is critical for treatment planning but has rarely been tested in severe/end-stage disease. We compared the performance of the Disc Damage Likelihood Scale (DDLS) and cup:disc ratio (CDR) using a functional glaucoma staging system (GSS) as the reference standard.
METHODS: Post hoc analysis of a randomised controlled trial at the Eye Department of Kilimanjaro Christian Medical Centre, Tanzania. Eligible participants (aged ≥18 years) with open-angle glaucoma, intraocular pressure (IOP) of >21 mm Hg, were randomised to timolol 0.5% eye drops or selective laser trabeculoplasty. Fundoscopy established vertical and horizontal CDRs and DDLS. Visual acuity and static visual fields were graded (GSS). The study used area under the receiver operating characteristic (AROC) curves and Spearman's rank correlation coefficients to compare staging systems. Logistic regression with generalised estimating equations determined risk factors of functional severe/end-stage glaucoma.
RESULTS: 382 eyes (201 participants) were evaluated; 195 (51%) had severe or end-stage glaucoma; mean IOP was 26.7 (SD 6.9) mm Hg. DDLS yielded an AROC of 0.90 (95% CI 0.87 to 0.93), vertical cup:disc ratio (vCDR) of 0.88 (95% CI 0.85 to 0.91, p=0.048) for identifying severe/end-stage disease. Correlation coefficients comparing GSS to DDLS and vCDRs were 0.73 and 0.71, respectively. Advanced structural stages, vision impairment, higher IOP and less financial resources were risk factors of functional severe/end-stage glaucoma.
CONCLUSION: This study indicates that both structural staging systems can differentiate severe/end-stage glaucoma from less severe disease, with a moderate advantage of DDLS over CDR. Clinical examination of the optic disc plays an important role in addition to functional assessment when managing severe/end-stage glaucoma.
Procedural circuit Deficit Hypothesis (PDH) of Developmental Language Disorder (DLD) predicts problems with learning and retention of grammar. Twenty 7- to 9-year-old Cantonese-speaking children with DLD and their typically developing (TD) age peers participated in a syntactic priming task that was given in two sessions one week apart. Production of Indirect Object Relative Clause (IORC) was tested using a probe test before and after the priming task, and one week later. The study involved two cycles of learning and retention, and two levels of prior knowledge. Bayesian linear mixed effects modelling was used for data analysis. Children with DLD learned, and possibly retained, IORC less well than TD children after age, working memory and general grammatical knowledge were controlled for. No interaction effects were significant, meaning that cycle and prior knowledge affected both groups similarly in learning and retention. Results were discussed in relation to PDH and the Complementary Learning Systems Theory.
Thirty-three adult (≥18 years of age) patients with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will also undergo surgery for tumor resection. This group will be included for comparison.
Residual motor deficits are common after stroke and often have a negative impact on the performance of functional activities and overall quality of life. A frequently reported contribution to these functional limitations is an inability to incorporate the weaker arm and hand into daily activities. While rehabilitation interventions can improve arm functional capacity, these improvements often do not translate into increased real-world arm use which is often reduced after stroke.

The performance of skilled arm and hand movements in standing requires precise coordination between upper extremity movement and balance control. Many everyday functional tasks that require the arm are performed in standing (e.g. opening a door or meal preparation at the kitchen counter), however, training of arm function in rehabilitation is often done in sitting. An important rehabilitation approach may be to create a training environment that resembles the way the arm is used in everyday life (i.e. standing). This study will examine the feasibility of providing task-oriented, functional arm training in standing and during walking in individuals with motor deficits due to stroke.
PURPOSE:To obtain the title agent containing at least one or more polypeptides BUF-4 and BUF-5 as active ingredients, having bone formation promoting action, reduced in side effects and useful in fundamental remedy for osteoporosis. CONSTITUTION:At least one or more polypeptides BUF-4 and BUF-5 among the polypeptides are blended as active ingredients and prepared according to an ordinary method to provide the aimed product. The aimed product is mainly prepared in an injection (e.g. intravenous, hypodermic or intramuscular injection) and formulated also in agent form of capsule, tablet, etc. Dose of the active ingredients are 0.05-200mg/adult day. The aimed remedy has low antigen, since the remedy has limation of bone unlike a conventional active vitamin D3, calcitonin, etc., and is human derived protein and can be used for a long period, since the remedy hardly cause allergy.
The present invention relates to a Chinese medicine composition for treating children dyspepsia and a preparing method thereof. The Chinese medicine composition is prepared by scorch-fried whitethorn, scorch-fried medicated leaven, scorch-fried malt, scorch-fried betel nut, scutellaria, pummelo peel, amomum villosum, bitter orange (bran-fried), citrus aurantium L.var.amara Engl.,chicken's gizzard-skin (stir-fried), radish seeds (stir-fried) and approximate medicinal supplementary material. The Chinese medicine composition is mainly used for treating symptoms of children anorexia, anorexia, food and milk taking stoppage, belching expanding and children simplicity indigestion caused by spleen qi disagreement. The children eat-promoting pellet of the invention has the efficacies of promoting digestion, eliminating stagnation, enlivening spleen, regulating stomach, etc. The children eat-promoting pellet can quickly alleviate the symptoms of sallow complexion, anorexia, expanded stomach, slow pulse, etc. Furthermore the Chinese medicine composition has the advantages of convenient taking, small dose, no toxic or side effect and is easily accepted by children.